|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 26.50 DKK | +0.38% |
|
0.00% | -18.46% |
| 04-29 | Nordea cuts Embla price target to DKK 34 (38), reiterates Buy | FW |
| 04-28 | Embla Medical hf., Q1 2026 Earnings Call, Apr 28, 2026 |
Business description: Embla Medical hf.
Number of employees: 4,500
Sales by Activity: Embla Medical hf.
| Fiscal Period: December | 2021 (USD) | 2022 (USD) | 2023 (USD) | 2024 (USD) | 2025 (USD) |
|---|---|---|---|---|---|
Prosthetics & Neuro Orthotics | 453M | 456M | 398M | 451M | 513M |
Bracing and Supports (Incl.Compression Therapy (Phlebology)) | 266M | 263M | 146M | 148M | 148M |
Patient Care | - | - | 280M | 294M | 306M |
Internal Product Sales | - | - | -38.95M | -38.52M | -39.04M |
Geographical breakdown of sales: Embla Medical hf.
| Fiscal Period: December | 2021 (USD) | 2022 (USD) | 2023 (USD) | 2024 (USD) | 2025 (USD) |
|---|---|---|---|---|---|
Europe Middle-East and Africa (EMEA) | 733M | 761M | 807M | 904M | 1.07B |
Americas | 439M | 454M | 518M | 553M | 635M |
Asia-Pacific (APAC) | 74.24M | 74.96M | 69.98M | 72.08M | 78.06M |
Eliminations | -528M | -571M | -609M | -675M | -853M |
Executive Committee: Embla Medical hf.
| Manager | Title | Age | Since |
|---|---|---|---|
Sveinn Sölvason
CEO | Chief Executive Officer | 48 | 31/03/2022 |
| Director of Finance/CFO | 60 | 31/08/2022 | |
Andr Rocha
CTO | Chief Tech/Sci/R&D Officer | - | 23/02/2025 |
Lukas Märklin
COO | Chief Operating Officer | 52 | 14/06/2023 |
Klaus Sindahl
IRC | Investor Relations Contact | - | 30/04/2024 |
Composition of the Board of Directors: Embla Medical hf.
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 58 | 31/12/2008 | |
Niels Jacobsen
CHM | Chairman | 68 | 31/12/2005 |
Svafa Grönfeldt
BRD | Director/Board Member | 61 | 31/01/2008 |
| Director/Board Member | 69 | 07/03/2021 | |
| Director/Board Member | 47 | 29/02/2024 | |
Tina Olesen
BRD | Director/Board Member | 54 | 29/02/2024 |
Holdings: Embla Medical hf.
| Name | Stocks | % | Valuation |
|---|---|---|---|
EMBLA MEDICAL HF. 0.16% | 702,442 | 0.16% | 3 M $ |
Company details: Embla Medical hf.
Group companies: Embla Medical hf.
| Name | Category and Sector |
|---|---|
Össur Iceland ehf
 Össur Iceland ehf Medical SpecialtiesHealth Technology Provides non-invasive orthopedic products and support services |
Medical Specialties
|
Össur Finance AG |
Medical Prosthetics
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.38% | 0.00% | -18.46% | -18.08% | 1.73B | |
| -3.66% | -3.38% | -3.24% | -31.29% | 19.75B | |
| 0.00% | +2.47% | -9.72% | -13.27% | 15.23B | |
| -3.16% | -1.95% | -61.18% | -48.71% | 5.64B | |
| +7.81% | +15.08% | - | - | 4.25B | |
| -3.41% | +0.48% | +37.47% | +10.49% | 1.66B | |
| +3.14% | +5.56% | -36.09% | -59.08% | 1.25B | |
| -2.53% | +5.93% | +76.39% | +136.13% | 894M | |
| -2.50% | -4.96% | +14.22% | +159.60% | 444M | |
| -8.35% | -9.17% | - | - | 240M | |
| Average | -2.14% | +1.48% | -0.08% | +16.97% | 5.11B | |
| Weighted average by Cap. | -2.01% | +1.02% | -10.67% | -21.24% |
Sector
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- EMBLA Stock
- Company Embla Medical hf.
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition